2014


Для доступа к данному материалу пожалуйста авторизуйтесь или зарегистрируйтесь

Зарегистрируйтесь Авторизуйтесь
2014/№6

Бета-адреноблокаторы и пульсурежающая терапия: взгляд практического врача


Тарловская Е. И.

ГБОУ ВПО «Кировская ГМА» МЗ РФ, 610027, Киров, ул. К. Маркса, д. 112


Ключевые слова: артериальная гипертензия, бета-адреноблокаторы, инфаркт миокарда, 
ишемическая болезнь сердца, пульсурежающая терапия, сердечная недостаточность


DOI: 10.18087/rhj.2014.6.2028

В обзорной статье представлены современные данные о применении β-АБ в качестве пульсурежающей терапии при различных ССЗ. Материал изложен в соответствии с Рекомендациями международных кардиологических сообществ последних лет. Отмечены положения с высоким классом и уровнем доказательности, а также представлены альтернативные точки зрения.

  1. Bemelmans RH, Visseren FL. The resting heart rate. Ned Tijdschr Geneeskd. 2014;158 (13):A6931.
  2. Fox K, Ford I, Steg PG et al. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet. 2008;372 (9641):8 17–21.
  3. Pepine CJ, Handberg-Thurmond E, Marks RG et al. Rationale and design of the International Verapamil SR / Trandolapril Study (INVEST): an internet – based randomized trial in coronary artery disease patients with hypertension. JACC. 1998 Nov 1; (32) (5):1228–37.
  4. Achenbach S, Andreotti F, Arden C et al. 2013 ESC guidelines on the management of stable coronary artery disease. Eur Heart J. 2013 Oct 7;34 (38):2949–3003.
  5. Bangalore S, Messerli FH, Ou FS et al. The association of admission heart rate and in-hospital cardiovascular events in patients with non-ST-segment elevation acute coronary syndromes: results from 135 164 patients in the CRUSADE quality improvement initiative. Eur Heart J. 2010 Mar;31 (5):552–60.
  6. Böhm M, Swedberg K, Komajda M, Borer JS Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet. 2010 Sep 11;376 (9744):886–94.
  7. Bohm M, Borer J, Ford I et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clin Res Cardiol. 2013 Jan;102 (1):11–22.
  8. McMurray JJ, Adamopoulos S, Anker SD et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Eur Heart J. 2012 Jul;33 (14):1787–847.
  9. Мареев В. Ю., Агеев Ф. Т., Арутюнов Г. П. и др. Национальные рекомендации ОССН, РКО и РНМОТ по диагностике и лечению ХСН (четвертый пересмотр) Журнал Сердечная Недостаточность. 2013;14 (7):379–472.
  10. Palatini P, Benetos A, Julius S. Impact of increased heart rate on clinical outcomes in hypertension: implications for antihypertensive drug therapy. Drugs. 2006;66 (2):133–44.
  11. Palatini P, Reboldi G, Beilin LJ et al. Predictive value of night-time heart rate for cardiovascular events in hypertension. The ABP-International study. Int J Cardiol. 2013 Sep 30;168 (2):1490–5.
  12. Salles GF, Cardoso CR, Fonseca LL et al. Prognostic significance of baseline heart rate and its interaction with beta-blocker use in resistant hypertension: a cohort study. Am J Hypertens. 2013 Feb;26 (2):218–26.
  13. Julius S, Palatini P, Kjeldsen SE et al. Usefulness of heart rate to predict cardiac events in treated patients with high-risk systemic hypertension. Am J Cardiol. 2012 Mar 1;109 (5):685–92.
  14. Okin PM, Kjeldsen SE, Julius S et al. Effect of changing heart rate during treatment of hypertension on incidence of heart failure. Am J Cardiol. 2012 Mar 1;109 (5):699–704.
  15. Okin PM, Wachtell K, Kjeldsen SE et al. Incidence of atrial fibrillation in relation to changing heart rate over time in hypertensive patients: the LIFE study. Circ Arrhythm Electrophysiol. 2008 Dec;1 (5):337–43.
  16. Palatini P, Thijs L, Staessen JA et al. Predictive value of clinic and ambulatory heart rate for mortality in elderly subjects with systolic hypertension. Arch Intern Med. 2002 Nov 15;162 (20):2313–21.
  17. Bangalore S, Sawhney S, Messerli FH. Relation of beta-blocker-induced heart rate lowering and cardioprotection in hypertension. J Am Coll Cardiol. 2008 Oct 28;52 (18):1482–9.
  18. Bangalore S, Messerli FH, Kostis JB, Pepine CJ. Cardiovascular protection using beta-blockers: a critical review of the evidence. J Am Coll Cardiol. 2007 Aug 14;50 (7):563–72.
  19. Manisty CH, Hughes AD. Meta-analysis of the comparative effects of different classes of antihypertensive agents on brachial and central systolic blood pressure, and augmentation index. Br J Clin Pharmacol. 2013 Jan;75 (1):79–92.
  20. Wiysonge CS, Bradley HA, Volmink J et al. Beta-blockers for hypertension. Cochrane Database Syst Rev. 2012;8: CD002003.
  21. De Caterina AR, Leone AM. Why beta-blockers should not be used as first choice in uncomplicated hypertension. Am J Cardiol. 2010 May 15;105 (10):1433–8.
  22. Warmack TS, Estes MA, Heldenbrand S, Franks AM. Beta-adrenergic antagonists in hypertension: a review of the evidence. Ann Pharmacother. 2009 Dec;43 (12): 2031–43.
  23. Chrysant SG, Chrysant GS. Current status of β-blockers for the treatment of hypertension: an update. Drugs Today. 2012 May;48 (5):353–66.
  24. Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH / ESC guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013 Jul 21;34 (28):2159–219.
  25. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009 May 23;338 (7705):1245.
  26. Bangalore S, Steg G, Deedwania P et al. β-blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012 Oct 3;308 (13):1340–9.
  27. Козиолова Н. А. Бета-адреноблокаторы в лечении инфаркта миокарда и стабильной ишемической болезни сердца: спорные вопросы и неопровержимые доказательства. Фарматека. 2013;13:12–21.
  28. Гиляревский С. Р., Орлов В. А., Кузьмина И. М. и др. Изменение представлений о роли бета-блокаторов в лечении сердечно-сосудистых заболеваний. Русский медицинский журнал. 2013;4:231–6.
  29. Bangalore S, Makani H, Radford M et al. Clinical Outcomes with β-blockers for Myocardial Infarction A Meta-Analysis of Randomized Trials. Am J Med. 2014 Oct;127 (10):939–53.
  30. Roberts R, Rogers WJ, Mueller HS et al. Immediate versus deferred beta-blockade following thrombolytic therapy in patients with acute myocardial infarction: results of the thrombolysis in myocardial infarction (TIMI) II-B study. Circulation. 1991 Feb;83 (2):422–37.
  31. Van de Werf F, Janssens L, Brzostek T et al. Short-term effect of early intravenous treatment with beta-adrenergic blocking agents or a specific bradycardia agent in patients with acute myocardial infarction receiving thrombolytic therapy. J Am Coll Cardiol. 1993 Aug;22 (2):407–16.
  32. Barron HV, Rundle AC, Gore JM et al. Intracranial hemorrhage rates and effect of immediate beta-blocker use in patients with acute myocardial infarction treated with tissue plasminogen activator. Am J Cardiol. 2000 Feb 1;85 (3):294–8.
  33. Emery M, López-Sendón J, Steg PG et al. Patterns of use and potential impact of early beta-blocker therapy in non-ST-elevation myocardial infarction with and without heart failure: the Global Registry of Acute Coronary Events. Am Heart J. 2006 Dec;152 (6):1015–21.
  34. Miller CD, Roe MT, Mulgund J et al. Impact of acute beta-blocker therapy for patients with non-ST-segment elevation myocardial infarction. Am J Med. 2007 Aug;120 (8):685–92.
  35. Gunnell AS, Einarsdóttir K, Sanfilippo F et al. Improved long-term survival in patients on combination therapies following an incident acute myocardial infarction: a longitudinal population-based study. Heart. 2013 Sep;99 (18):1353–8.
  36. Fihn SD, Gardin JM, Abrams J et al. 2012 ACCF / AHA / ACP / AATS / PCNA / SCAI / STS Guideline for the diagnosis and mana­gement of patients with stable ischemic heart disease. J Am Coll Cardiol. 2012 Dec 18;60 (24):e44‑e164.
  37. Hamm CW, Bassand JP, Agewall S et al. ESC Guidelines for the management of acute coronary syndromes in patients presen­ting without persistent ST-segment elevation. Eur Heart J. 2011 Dec;32 (23):2999–3054.
  38. Packer M, Bristow MR, Cohn JN et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 1996 May 23;334 (21):1349–55.
  39. Leizorovicz A, Lechat P, Cucherat M, Bugnard F. Bisoprolol for the treatment of chronic heart failure: a meta-analysis on individual data of two placebo-controlled studies-CIBIS and CIBIS II. Cardiac Insufficiency Bisoprolol Study. Am Heart J. 2002 Feb;143 (2):301–7.
  40. Poole-Wilson PA, Swedberg K, Cleland JG et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet. 2003 Jul 5;362 (9377):7–13.
  41. Domanski MJ, Krause-Steinrauf H, Massie BM et al. A comparative analysis of the results from 4 trials of beta-blocker therapy for heart failure: BEST, CIBIS-II, MERIT-HF, and COPERNICUS. J Card Fail. 2003 Oct;9 (5):354–63.
  42. Verbrugge FH, Duchenne J, Bertrand PB et al. Uptitration of renin-angiotensin system blocker and beta-blocker therapy in patients hospitalized for heart failure with reduced versus preserved left ventricular ejection fractions. Am J Cardiol. 2013 Dec 15;112 (12):1913–20.
  43. Franke J, Wolter JS, Meme L et al. Optimization of pharmacotherapy in chronic heart failure: is heart rate adequately addressed? Clin Res Cardiol. 2013 Jan;102 (1):23–31.
  44. Rienstra M, Damman K, Mulder BA et al. Beta-blockers and outcome in heart failure and atrial fibrillation. A meta-analysis. J Am Coll Cardiol HF. 2013 Feb;1 (1):21–8.
  45. Kao DP, Davis G, Aleong R et al. Effect of bucindolol on heart failure outcomes and heart rate response in patients with reduced ejection fraction heart failure and atrial fibrillation. Eur J Heart Fail. 2013 Mar;15 (3):324–33.
  46. Stankovic I, Neskovic AN, Putnikovic B et al. Sinus rhythm versus atrial fibrillation in elderly patients with chronic heart failure – insight from the Cardiac Insufficiency Bisoprolol Study in Elderly. Int J Cardiol. 2012 Nov 29;161 (3):160–5.
  47. Stecker EC, Fendrick AM, Knight BP, Aaronson KD. Prophylactic pacemaker use to allow beta-blocker therapy in patients with chronic heart failure with bradycardia. Аm Heart J. 2006 Apr;151 (4):820–8.
Тарловская Е. И. Бета-адреноблокаторы и пульсурежающая терапия: взгляд практического врача. Сердце: журнал для практикующих врачей. 2014;13 (6):383–388.

Для доступа к данному материалу пожалуйста авторизуйтесь или зарегистрируйтесь

Зарегистрируйтесь Авторизуйтесь
Ru En